Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences announces initial shipments of its next-generation PCT System

Pressure BioSciences, Inc. announces the initial shipments of its recently released, next-generation pressure cycling technology-based instrument, the Barocycler 2320EXTREME
Pressure BioSciences announces initial shipments of its next-generation PCT System
Three Barocycler 2320EXTREME devices destined near Sydney

Pressure BioSciences, Inc. (OTCMKTS:PBIO) announced the initial shipments of its recently released, next-generation pressure cycling technology ("PCT")-based instrument, the Barocycler 2320EXTREME on Thursday. 

Five instruments were recently purchased and delivered: one to an Ivy-league school with a rich history in life sciences research, one to the company's exclusive distributor in China, and the remaining three to the Children's Medical Research Institute ("CMRI") near Sydney Australia.

The instruments purchased by CMRI will be used in cancer research studies by the newly established Australian Cancer Research Foundation International Centre for the Proteome of Cancer ("ProCan"), located in the CMRI facility.

ProCan has announced plans to analyse approximately 70,000 cancer tumor samples over the next seven years with state-of-the-art protein profiling instruments and other tools. Data from their studies are expected to enable discoveries around the causes of cancer, provide guidance on cancer treatment options, and generate standard operating procedures that can be used in cancer testing laboratories worldwide.

In their studies, ProCan will combine PBI's new Barocycler 2320EXT system for sample preparation with SCIEX's SWATH data independent-acquisition mass spectrometry workflow on Triple TOF 6600 Systems.  SCIEX is a global leader in life science analytical technologies. 

In January 2016, PBI and SCIEX announced an exclusive, two-year, worldwide co-marketing agreement under which PBI and SCIEX will co-promote PBI's PCT systems with SCIEX's SWATH-based proteomics workflows.

In his 2016 State-of-the-Union message, President Barack Obama introduced the $1bn 'Cancer Moonshot' initiative, with a goal to accelerate research in cancer, to break down existing barriers that stymie progress, and to support other changes that will improve the ability to prevent, detect, treat, and cure cancer. Vice-President Biden was asked to lead this effort.

On July 16, the White House named ProCan as one of four preeminent cancer centers in Australia chosen to collaborate with the US National Cancer Institute in the "Cancer Moonshot" initiative.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use